Novo Nordisk A/S (NOV) Stock Price & News

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia

About Novo Nordisk A/S

CEOMaziar Mike Doustdar

Employees66.7K

FoundedDec 21, 1923

HeadquartersBagsværd, Capital Region of Denmark, Denmark

SectorPharmaceutical industry

Websitenovonordisk.com

All values in DKK	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	74.98B	79.14B	96.82B	78.49B
Cost of goods sold	14.47B	14.17B	13.60B	17.10B
Cost of revenue	14.47B	14.17B	13.60B	17.10B
Research and development expenses	11.49B	12.67B	10.28B	11.46B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	15.76B	17.14B	13.22B	16.31B
Operating expense	27.25B	29.73B	23.61B	28.00B
Total operating expenses	41.72B	43.90B	37.20B	45.10B
Operating income	33.25B	35.24B	59.62B	33.39B
Other non operating income	1.53B	-241.00M	-	-
EBT including unusual items	25.52B	34.18B	62.17B	26.88B
EBT excluding unusual items	35.09B	37.62B	62.17B	33.20B
Income tax expense	5.51B	7.29B	13.62B	5.89B
Effective tax rate	21.60%	21.34%	21.90%	21.90%
Other operating expenses	-	-81.00M	106.00M	234.00M
Net income	20.01B	26.89B	48.56B	20.99B
Net profit margin	26.68%	33.98%	50.15%	26.74%
Earnings per share	4.50	6.04	6.63	6.18
Interest and investment income	307.00M	4.41B	-	1.31B
Interest expense	-	-4.97B	-	-1.50B
Net interest expenses	307.00M	-560.00M	-	-186.00M
Depreciation and amortization charges	-	-	-	-
EBITDA	36.49B	36.66B	63.13B	36.99B
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything